CJC-1295 No DAC / Ipamorelin

CJC-1295 No DAC / Ipamorelin Combination

The most popular GH optimization combination — GHRH and GHRP working synergistically for maximum physiological GH release.

100% 50% · t½ Time → Serum level
Molecular Weight Not specified
Half-Life Varies
Typical Dose 0.5 mg to 1.5 mg
Cycle Length 8–16 weeks

Description

The CJC-1295 No DAC / Ipamorelin combination is the most widely used GH optimization protocol. CJC-1295 No DAC provides the GHRH stimulus while Ipamorelin amplifies the GH pulse, producing synergistic GH release with physiological pulsatility.

Key Characteristics

Molecular Formula

Molecular Weight

Half-Life

Administration Routes

Subcutaneous injection

Typical Dose

0.5 mg to 1.5 mg

Frequency

2–3x daily

Investigated Benefits

* Benefits based on preclinical/animal research unless otherwise noted.

Mechanism of Action

“The most popular GH optimization combination — GHRH and GHRP working synergistically for maximum physiological GH release.”

CJC-1295 No DAC activates GHRH receptors to stimulate GH synthesis. Ipamorelin activates GHS-R1a to amplify the GH pulse. The combination produces 3–5x greater GH release than either peptide alone while maintaining natural pulsatility.

Administration Routes

Subcutaneous injection

Key Characteristics

Typical Dose

0.5 mg to 1.5 mg

Frequency

2–3x daily

Cycle Length

8–16 weeks

Administration

Subcutaneous injection

Protocol Notes

Inject both peptides simultaneously or within minutes of each other. Administer on empty stomach. Bedtime dose is most important. Monitor IGF-1 every 3 months.

Reconstitution Guide

Per prescriber instructions or individual vial reconstitution.

Storage Information

Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days.

Quality & Sourcing Standards

When sourcing CJC-1295 No DAC / Ipamorelin for research purposes, the following quality benchmarks should be verified before use.

Purity:

>98% (verified by HPLC)

Certificate of Analysis (COA):

Must be provided by supplier

Endotoxin Testing:

<0.1 EU/mg (prevents bacterial contamination)

GMP Compliance:

Manufactured in cGMP-certified facility

Third-Party Testing:

Independent lab verification preferred

Storage Information

Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days.

FDA Disclaimer

The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.

Research Highlights

1

Most widely used GH optimization combination in clinical practice

2

Synergistic GH release well-documented

3

Physiological pulsatility maintained vs continuous GH infusion

Evidence Level

Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited.

Compatible Peptides

Peptides commonly used alongside CJC-1295 No DAC / Ipamorelin for synergistic effects.

BPC-157

A synthetic pentadecapeptide derived from gastric juice with extraordinary tissue healing properties across multiple organ systems.

IGF-1 LR3

A long-acting analog of IGF-1 with enhanced receptor binding and extended half-life for anabolic and recovery effects.

TB-500

A synthetic analog of Thymosin Beta-4 that promotes systemic healing through actin regulation and angiogenesis.

Quick Reference

Category

Blends & Combos

Status

Research Only
 

Dose

0.5 mg to 1.5 mg

Frequency

2–3x daily

Cycle

8–16 weeks